Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Japanese Journal of Ophthalmology
Published in: Japanese Journal of Ophthalmology 3/2013

01-05-2013 | Clinical Investigation

Two-year results of reduced-fluence photodynamic therapy combined with intravitreal ranibizumab for typical age-related macular degeneration and polypoidal choroidal vasculopathy

Authors: Yusaku Yoshida, Takeya Kohno, Manabu Yamamoto, Tasuku Yoneda, Hisashi Iwami, Kunihiko Shiraki

Published in: Japanese Journal of Ophthalmology | Issue 3/2013

Login to get access

Abstract

Purpose

To report the 2-year results of reduced-fluence photodynamic therapy (RF-PDT) combined with intravitreal ranibizumab (IVR) for typical age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV).

Methods

Twenty-four previously untreated eyes of 23 AMD patients with decimal best-corrected visual acuity (BCVA) of less than 0.7 received the combined therapy, followed by retreatments as needed over the subsequent 2 years. When the BCVA was better than or equal to 0.7, only 3 monthly IVR injections were performed during the retreatment.

Results

The BCVAs were maintained in 7 of 10 typical AMD eyes and in 13 of 14 PCV eyes at month 24. The mean BCVA improved in the PCV group (P < 0.05) but not in the typical AMD group. The central foveal thickness decreased in both groups (P < 0.01, P < 0.001). The mean numbers of the total PDT and IVR injections were 1.8 and 7.2 in the typical AMD group and 1.8 and 6.4 in the PCV group.

Conclusion

After RF-PDT combined therapy with administration of retreatments as needed that consisted of either 3 IVR injections alone or combined therapy, the BCVA was maintained in typical AMD and improved in PCV during a 2-year follow-up period.
Literature
1.
Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419–31.PubMedCrossRef
2.
Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology. 2009;116:57–65.PubMedCrossRef
3.
Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol. 2009;148:43–58.PubMedCrossRef
4.
Holz FG, Amoaku W, Donate J, Guymer RH, Kellner U, Schlingemann RO, et al. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmology. 2011;118:663–71.PubMedCrossRef
5.
Dhalla MS, Shah GK, Blinder KJ, Ryan EH Jr, Mittra RA, Tewari A, et al. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration. Retina. 2006;26:988–93.PubMedCrossRef
6.
Lazic R, Gabric N. Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration. Ophthalmology. 2007;114:1179–85.PubMedCrossRef
7.
Costa RA, Jorge R, Calucci D, Melo LA, Cardillo JA, Scott IU. Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study). Graefe’s Arch Clin Exp Ophthalmol. 2007;245:1273–80.CrossRef
8.
Ahmadieh H, Taei R, Soheilian M, Riazi-Esfahani M, Ahadi H. Single-session photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration. Eur J Ophthalmol. 2008;18:297–300.PubMed
9.
Ladewig MS, Karl SE, Hamelmann V, Helb HM, Scholl HP, Holz FG, et al. Combined intravitreal bevacizumab and photodynamic therapy for neovascular age-related macular degeneration. Graefe’s Arch Clin Exp Ophthalmol. 2008;246:17–25.CrossRef
10.
Smith BT, Dhalla MS, Shah GK, Blinder KJ, Ryan EH Jr, Mittra RA. Intravitreal injection of bevacizumab combined with verteporfin photodynamic therapy for choroidal neovascularization in age-related macular degeneration. Retina. 2008;28:675–81.PubMedCrossRef
11.
Kaiser PK. Verteporfin photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration. Ophthalmology. 2009;116:747–55.PubMedCrossRef
12.
Hara R, Kawaji T, Inomata Y, Tahara J, Sagara N, Fukushima M, et al. Photodynamic therapy alone versus combined with intravitreal bevacizumab for neovascular age-related macular degeneration without polypoidal choroidal vasculopathy in Japanese patients. Graefes Arch Clin Exp Ophthalmol. 2010;248:931–6.PubMedCrossRef
13.
Spielberg L, Leys A. Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years. Graefes Arch Clin Exp Ophthalmol. 2010;248:943–56.PubMedCrossRef
14.
Lim JY, Lee SY, Kim JG, Lee Jy, Chung H, Yoon YH. Intravitreal bevacizumab alone versus in combination with photodynamic therapy for the treatment of neovascular maculopathy in patients aged 50 years or older: 1-year results of a prospective clinical study. Acta Ophthalmol. 2012;90:61–7.PubMedCrossRef
15.
Larsen M, Schmidt-Erfurth U, Lanzetta P, Wolf S, Simader C, Tokaji E, et al. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration. Twelve-month MONT BLANC Study Results. Ophthalmology. 2012;119:992–1000.PubMedCrossRef
16.
Kaiser PK, Boyer DS, Cruess AF, Slakter JS, Pilz S, Weisberger A, et al. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration. Twelve-month results of the DENALI study. Ophthalmology. 2012;119:1001–10.PubMedCrossRef
17.
Schmidt-Erfurth U, Michels S, Barbazetto I, Laqua H. Photodynamic effects on choroidal neovascularization and physiological choroid. Invest Ophthalmol Vis Sci. 2002;43:830–41.PubMed
18.
Schmidt-Erfurth U, Schlötzer-Schrehard U, Cursiefen C, Michels S, Beckendorf A, Naumann GO. Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest Ophthalmol Vis Sci. 2003;44:4473–80.PubMedCrossRef
19.
Azab M, Boyer DS, Bressler NM, Bressler SB, Cihelkova I, Hao Y, et al. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial. Arch Ophthalmol. 2005;123:448–57.PubMedCrossRef
20.
Potter MJ, Claudio CC, Szabo SM. A randomised trial of bevacizumab and reduced light dose photodynamic therapy in age-related macular degeneration: the VIA study. Br J Ophthalmol. 2010;94:174–9.PubMedCrossRef
21.
Costagliola C, Romano MR, Rinaldi M, dell’Omo R, Chiosi F, Menzione M, et al. Low fluence rate photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration. Br J Ophthalmol. 2010;94:180–4.PubMedCrossRef
22.
Chan WM, Lam DSC, Lai TY, Liu DT, Li KK, Yao Y, et al. Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy. One-year results of a prospective case series. Ophthalmology. 2004;111:1576–84.PubMedCrossRef
23.
Koh A, Lee WK, Chen LJ, Chen SJ, Hashad Y, Kim H, et al. EVEREST STUDY. Efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina. 2012;32:1453–64.PubMedCrossRef
24.
Hirami Y, Tsujikawa A, Otani A, Yodoi Y, Aikawa H, Mandai M, et al. Hemorrhagic complications after photodynamic therapy for polypoidal choroidal vasculopathy. Retina. 2007;27:335–41.
25.
Yamashita A, Shiraga F, Shiragami C, Ono A, Tenkumo K. One-year results of reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol. 2010;149:465–71.PubMedCrossRef
26.
Kurashige Y, Otani A, Sasahara M, Yodoi Y, Tamura H, Tsujikawa A, et al. Two-year results of photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol. 2008;146:513–9.
27.
Yamashiro K, Tsujikawa A, Nishida A, Mandai M, Kurimoto Y. Recurrence of polypoidal choroidal vasculopathy after photodynamic therapy. Jpn J Ophthalmol. 2008;52:457–62.PubMedCrossRef
28.
Akaza E, Yuzawa M, Mori R. Three-year follow-up results of photodynamic therapy for polypoidal choroidal vasculopathy. Jpn J Ophthalmol. 2011;55:39–44.PubMedCrossRef
29.
Sawa M, Iwata E, Ishikawa K, Gomi F, Nishida K, Terasaki H. Comparison of different treatment intervals between bevacizumab injection and photodynamic therapy in combined therapy for age-related macular degeneration. Jpn J Ophthalmol. 2012;56:470–5.PubMedCrossRef
30.
Augustin AJ, Puls S, Offermann I. Triple therapy for choroidal neovascularization due to age-related macular degeneration. verteporfin PDT, bevacizumab, and dexamethasone. Retina. 2007;27:133–40.PubMedCrossRef
31.
Sato T, Kishi S, Matsumoto H, Mukai R. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for polypoidal choroidal vasculopathy. Am J Ophthalmol. 2010;149:947–54.PubMedCrossRef
32.
Gomi F, Sawa M, Wakabayashi T, Sasamoto Y, Suzuki M, Tsujikawa M. Efficacy of intravitreal bevacizumab combined with photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol. 2010;150:48–54.PubMedCrossRef
33.
Ruamviboonsuk P, Tadarati M, Vanichvaranont S, Hanutsaha P, Pokawattana N. Photodynamic therapy combined with ranibizumab for polypoidal choroidal vasculopathy: results of a 1-year preliminary study. Br J Ophthalmol. 2010;94:1045–51.PubMedCrossRef
34.
Song MH, Ryu HW, Roh YJ. One-year results of intravitreal ranibizumab with or without photodynamic therapy for polypoidal choroidal vasculopathy. Ophthalmologica. 2011;225:119–26.CrossRef
35.
Kim M, Kim K, Kim do G, Yu SY, Kwakx HW. Two-year results of photodynamic therapy combined with intravitreal anti-vascular endothelial growth factor for polypoidal choroidal vasculopathy. Ophthalmologica. 2011;226:205–13.PubMedCrossRef
36.
Tomita K, Tsujikawa A, Yamashiro K, Ooto S, Tamura H, Otani A, et al. Treatment of polypoidal choroidal vasculopathy with photodynamic therapy combined with intravitreal injections of ranibizumab. Am J Ophthalmol. 2012;153:68–80.PubMedCrossRef
37.
Sagong M, Suho L, Chang W. Reduced-fluence photodynamic therapy combined with intravitreal bevacizumab for polypoidal choroidal vasculopathy. Am J Ophthalmol. 2012;153:873–82.PubMedCrossRef
38.
Kim KS, Lee WK. Bevacizumab for serous changes originating from a persistent branching vascular network following photodynamic therapy for polypoidal choroidal vasculopathy. Jpn J Ophthalmol. 2011;55:370–7.PubMedCrossRef
Metadata
Title
Two-year results of reduced-fluence photodynamic therapy combined with intravitreal ranibizumab for typical age-related macular degeneration and polypoidal choroidal vasculopathy
Authors
Yusaku Yoshida
Takeya Kohno
Manabu Yamamoto
Tasuku Yoneda
Hisashi Iwami
Kunihiko Shiraki
Publication date
01-05-2013
Publisher
Springer Japan
Published in
Japanese Journal of Ophthalmology / Issue 3/2013
Print ISSN: 0021-5155
Electronic ISSN: 1613-2246
DOI
https://doi.org/10.1007/s10384-013-0234-z

Other articles of this Issue 3/2013

Japanese Journal of Ophthalmology 3/2013 Go to the issue

Laboratory Investigation

Vasodilatory effects of antivascular endothelium growth factor (VEGF) antibody, corticosteroid, and nitric oxide on the posterior ciliary arteries

Clinical Investigation

Predictive value of preoperative optical coherence tomography for visual outcome following macular hole surgery: effects of imaging alignment

Clinical Investigation

Branch retinal vein occlusion-associated subretinal hemorrhage

Erratum

Erratum to: Long-term intraocular pressure changes after combined phacoemulsification, intraocular lens implantation, and vitrectomy

Clinical Investigation

Concentric division of 10° visual field tests in retinitis pigmentosa

Clinical Investigation

Trabecular meshwork depigmentation in Vogt–Koyanagi–Harada disease